Prognostic Factors in Stereotactic Body Radiotherapy for Non–Small-Cell Lung Cancer (original) (raw)
Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): Is FDG-PET a predictor of outcome?
John Cho
Radiotherapy and Oncology, 2012
View PDFchevron_right
Assessing the Usefulness of 18 F-fluorodeoxyglucose PET-CT Scan After Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer
Travis Greer
Chest, 2014
View PDFchevron_right
Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after Stereotactic Body Radiotherapy
Hirofumi Fujii
Journal of Thoracic Oncology, 2014
View PDFchevron_right
Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy
Heunglae Cho
Radiation Oncology Journal
View PDFchevron_right
Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer
Naoko Sanuki
Lung Cancer, 2013
View PDFchevron_right
Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?
José Belderbos
Journal of Thoracic Oncology, 2012
View PDFchevron_right
The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT)
Naoko Sanuki
Radiotherapy and Oncology, 2011
View PDFchevron_right
Imaging features from pre-treatment CT scans are associated with clinical outcomes in non-small-cell lung cancer patients treated with stereotactic body radiotherapy
Thomas Dilling
Medical physics, 2017
View PDFchevron_right
Impact of PET-CT imaging on staging and conformal radiotherapy treatment planning for non small cell carcinoma of lung
Dilip Nikam
IP Journal of Diagnostic Pathology and Oncology, 2020
View PDFchevron_right
Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch® patient registry
John Lie Pablo
Radiation Oncology, 2015
View PDFchevron_right
Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Non–Small-Cell Lung Cancer
Quynh-thu Le
Clinical Lung Cancer, 2014
View PDFchevron_right
Clinical Outcome of Stereotactic Body Radiotherapy (SBRT) for Metastatic Lung Tumors using a Radiobiology-based Regimen
H. Ogino
International Journal of Radiation Oncology*Biology*Physics, 2011
View PDFchevron_right
Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer
June Yap
Radiotherapy and Oncology
View PDFchevron_right
Predictors of Nodal And Metastatic Failure in Early Stage Non-Small Cell Lung Cancer after Stereotactic Body Radiation Therapy
Mark Langer
International Journal of Radiation Oncology*Biology*Physics, 2018
View PDFchevron_right
18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study
Johannes Langendijk
European Journal of Nuclear Medicine and Molecular Imaging, 2011
View PDFchevron_right
Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT
Yuta Shibamoto
Radiation oncology (London, England), 2018
View PDFchevron_right
Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry
John Lie Pablo
Journal of Radiation Oncology, 2015
View PDFchevron_right
Clinical Outcomes of Single Dose Stereotactic Radiotherapy for Lung Metastases
Maurizio Valeriani, Mattia Falchetto Osti
Clinical Lung Cancer, 2013
View PDFchevron_right
Guidelines for the role of FDG-PET/CT in lung cancer management
Abdullah al-Harbi, Hamdan Al-jahdali
Journal of Infection and Public Health, 2012
View PDFchevron_right
Validation of high-risk CT features for detection of local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer
José Belderbos
International Journal of Radiation Oncology*Biology*Physics, 2016
View PDFchevron_right
Impact of Pretreatment Tumor Growth Rate on Outcome of Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy
Soha Atallah
International Journal of Radiation Oncology*Biology*Physics, 2014
View PDFchevron_right
Stereotactic body radiation therapy for early-stage non-small-cell lung cancer
Simon Lo
Expert Review of Anticancer Therapy, 2008
View PDFchevron_right
A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity
Laurie Gaspar
International Journal of Radiation Oncology*Biology*Physics, 2006
View PDFchevron_right
Clinical Outcomes of Stereotactic Body Radiotherapy for Small Lung Lesions Clinically Diagnosed as Primary Lung Cancer on Radiologic Examination
Takashi Mizowaki
International Journal of Radiation Oncology*Biology*Physics, 2009
View PDFchevron_right
Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non–small cell lung cancer
Rathan Subramaniam
The Journal of Thoracic and Cardiovascular Surgery, 2013
View PDFchevron_right
Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice
Peter Gerszten
Journal of Thoracic Oncology, 2013
View PDFchevron_right
Surgical Treatment of Local Recurrence After Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancers
Hiroshi Hamakawa
Journal of Thoracic Oncology, 2010
View PDFchevron_right
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2)
I. Brenot-rossi
European Journal of Nuclear Medicine and Molecular Imaging, 2014
View PDFchevron_right
The histologic effects of neoadjuvant stereotactic body radiation therapy (SBRT) followed by pulmonary metastasectomy—rationale and protocol design for the Post SBRT Pulmonary Metastasectomy (PSPM) trial
Housne Begum
Translational Cancer Research
View PDFchevron_right
Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non–small cell lung cancer treated with stereotactic body radiotherapy
Hideo Kawaguchi
Journal of Radiation Research, 2016
View PDFchevron_right
Prospective, Risk-Adapted Strategy of Stereotactic Body Radiotherapy for Early-Stage Non–Small-Cell Lung Cancer: Results of a Phase II Trial
Guy Storme
International Journal of Radiation Oncology*Biology*Physics, 2011
View PDFchevron_right
Interobserver Variability in the Computed Tomography Assessment of Pulmonary Injury and Tumor Recurrence After Stereotactic Body Radiotherapy
Isac Castro
View PDFchevron_right
The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: Results of a prospective study with mature survival data
Alan Herschtal
Radiotherapy and Oncology, 2013
View PDFchevron_right
Pretreatment [18F]-fluoro-2-deoxy-glucose Positron Emission Tomography Maximum Standardized Uptake Value as Predictor of Distant Metastasis in Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy: Rethinking the Role of Positron Emission Tomography in Personalizing Tre...
Vimoj nair
International Journal of Radiation Oncology*Biology*Physics, 2014
View PDFchevron_right